Physician profile
Todd A Patterson
NPI 1861459463
$1,041.26
in general payments reported to CMS, 2019-2025
15 companies · $156 in 2025
The $156 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $153 · 2021: $166 · 2022: $73.44 · 2023: $177 · 2024: $194 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $326.43 | 2019-2025 | Bexsero |
| Pfizer INC. | $130.20 | 2019-2024 | |
| Ironshore Pharmaceuticals INC. | $107.92 | 2022-2024 | Jornay Pm |
| Ultragenyx Pharmaceutical INC. | $73.15 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.17 | 2019-2021 | |
| Sanofi Pasteur INC. | $61.87 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $61.29 | 2024-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $43.54 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $30.13 | 2019-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
| Alexion Pharmaceuticals, INC. | $29.16 | 2019 | |
| Sobi, INC | $27.82 | 2023 | |
| Sanofi-Aventis U.S. LLC | $24.29 | 2024 | |
| Seqirus USA INC | $22.25 | 2025 | Flucelvax |
| Amneal Pharmaceuticals LLC | $16.59 | 2023 | Lyvispah |
| Kyowa Kirin, INC. | $14.45 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.